Coherus’ Neulasta Biosimilar Succeeds in Phase 3 Study

Coherus BioSciences has released positive results from a pharmacokinetic and pharmacodynamic study assessing its biosimilar candidate CHS-1701.

In the biosimilarity study comparing CHS-1701 to Amgen’s Neulasta, the candidate reached all of its co-primary endpoints.

Overall, there were no adverse events related to the treatment.